Abstract | BACKGROUND: The enduring presence of COVID-19 and subsequent increasing incidence of COVID-19 reinfection has prompted evaluation of associated risk factors, particularly the role of immunosuppression. OBJECTIVE: METHODS: This cross-sectional observational study leveraged the Pfizer global safety database (SDB) containing adverse event data collected in association with use of Pfizer products between 1 October 2019, and 30 June 2022. Selected Medical Dictionary for Drug Regulatory Activities (MedDRA®) Preferred Terms were used to identify COVID-19 cases; the search was further refined to comprise cases that subsequently reported events potentially indicative of COVID-19 reinfection. RESULTS: CONCLUSION: This pharmacovigilance study provides a characterization of cases indicative of COVID-19 reinfection with respect to reported use of immunosuppressant/ immunomodulating agents. The observations generated from this cross-sectional observational analysis may prompt further research into the role of immunosuppression in COVID-19 reinfection, in an effort to better inform clinical practice and patient management.
|
Authors | Elena Beyzarov, Yan Chen, Patrick Caubel |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 42
Issue 10
Pg. 807-812
(Oct 2022)
ISSN: 1179-1918 [Electronic] New Zealand |
PMID | 36100734
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2022. The Author(s). |
Chemical References |
- COVID-19 Vaccines
- Immunomodulating Agents
- Immunosuppressive Agents
- Pharmaceutical Preparations
|
Topics |
- Adverse Drug Reaction Reporting Systems
- COVID-19
(epidemiology)
- COVID-19 Vaccines
(administration & dosage)
- Cross-Sectional Studies
- Drug-Related Side Effects and Adverse Reactions
- Humans
- Immunomodulating Agents
(adverse effects)
- Immunosuppressive Agents
(adverse effects)
- Pharmaceutical Preparations
- Reinfection
(epidemiology)
|